|
SG10201601660YA
(en)
|
2007-09-18 |
2016-04-28 |
Takeda Vaccines Inc |
Method of conferring a protective immune response to norovirus
|
|
EP3299030B1
(en)
|
2011-07-11 |
2022-06-08 |
Takeda Vaccines, Inc. |
Parenteral norovirus vaccine formulations
|
|
US11344578B2
(en)
*
|
2017-04-19 |
2022-05-31 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
BR112020008568A2
(pt)
*
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
|
|
AU2019215034C1
(en)
|
2018-02-01 |
2022-01-06 |
Nkmax Co., Ltd. |
Method of producing natural killer cells and composition for treating cancer
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
CA3100341A1
(en)
|
2018-05-16 |
2019-11-21 |
Research Institute Of Nationwide Children's Hospital |
Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
BR112021019411A2
(pt)
*
|
2019-03-29 |
2021-11-30 |
Univ Texas |
Métodos para a produção de células car-nk e uso das mesmas
|
|
WO2020247392A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Nkarta, Inc. |
Combinations of engineered natural killer cells and engineered t cells for immunotherapy
|
|
KR102902719B1
(ko)
|
2019-10-18 |
2025-12-24 |
포티 세븐, 엘엘씨 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
US12195723B2
(en)
*
|
2019-11-08 |
2025-01-14 |
The Broad Institute, Inc. |
Engineered antigen presenting cells and uses thereof
|
|
CN115925976A
(zh)
*
|
2019-11-21 |
2023-04-07 |
博生吉医药科技(苏州)有限公司 |
Cd7-car-t细胞及其制备和应用
|
|
BR112022010225A2
(pt)
*
|
2019-11-27 |
2022-09-06 |
Univ Texas |
Transdução de car combinado em grande escala e edição de gene crispr de células nk
|
|
US20230045174A1
(en)
*
|
2019-11-27 |
2023-02-09 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of msc cells
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
BR112022013445A2
(pt)
*
|
2020-01-08 |
2022-09-13 |
Univ Texas |
Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos
|
|
WO2021202581A1
(en)
*
|
2020-03-30 |
2021-10-07 |
WUGEN, Inc. |
Engineered immune cells for adoptive cell therapy
|
|
CN113913458A
(zh)
*
|
2020-07-09 |
2022-01-11 |
杭州优凯瑞医药科技有限公司 |
非病毒方法制备稳定高表达嵌合受体的nk细胞
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
AU2021392809A1
(en)
*
|
2020-12-03 |
2023-07-20 |
Nkarta, Inc. |
Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
JP2023552895A
(ja)
|
2020-12-15 |
2023-12-19 |
ユニフェルシテイト アントウェルペン |
Ｃｄ７０をターゲティングする細胞ベースの治療剤
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
US11473060B2
(en)
|
2020-12-30 |
2022-10-18 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into NK cells
|
|
WO2022173737A1
(en)
|
2021-02-09 |
2022-08-18 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for freezing and thawing mammalian cells
|
|
CN113005151A
(zh)
*
|
2021-03-12 |
2021-06-22 |
广东药科大学 |
一种kdr-car-nk细胞的制备方法及其应用
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
PE20242205A1
(es)
|
2021-04-26 |
2024-11-19 |
Millennium Pharm Inc |
Anticuerpos anti-adgre2 y usos de los mismos
|
|
KR20240010717A
(ko)
*
|
2021-05-20 |
2024-01-24 |
우시 바이올로직스 아일랜드 리미티드 |
유전적으로 변형된 nk 세포들 및 이들의 용도
|
|
WO2022263682A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Onk Therapeutics Limited |
Double knockout natural killer cells
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN113599395B
(zh)
*
|
2021-09-22 |
2022-08-12 |
郑州源创吉因实业有限公司 |
含有nk细胞的治疗癌症的药物组合物
|
|
EP4408442A4
(en)
*
|
2021-10-01 |
2025-10-29 |
Univ Texas |
Immune cells loaded with antibodies and their methods of use in cancer treatment
|
|
US20240415885A1
(en)
*
|
2021-10-15 |
2024-12-19 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified NK cells
|
|
WO2023070079A1
(en)
*
|
2021-10-21 |
2023-04-27 |
Board Of Regents, The University Of Texas System |
Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof
|
|
WO2023081811A1
(en)
*
|
2021-11-04 |
2023-05-11 |
Saliogen Therapeutics, Inc. |
Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
|
|
TW202338085A
(zh)
|
2021-11-18 |
2023-10-01 |
美商健生生物科技公司 |
用於擴增自然殺手細胞製劑之無餵養細胞培養方法
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN114774364B
(zh)
*
|
2022-04-26 |
2024-04-26 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
AR130860A1
(es)
*
|
2022-10-25 |
2025-01-29 |
Takeda Pharmaceuticals Co |
Composiciones de linfocitos nk del receptor quimérico adgre2 y métodos de uso
|
|
JP2025536042A
(ja)
*
|
2022-11-10 |
2025-10-30 |
オーエヌケイ セラピューティクス リミテッド |
免疫調節薬を用いた併用療法
|
|
CN115947869B
(zh)
*
|
2022-11-28 |
2023-12-12 |
广州佰芮慷生物科技有限公司 |
一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途
|
|
CN115948344A
(zh)
*
|
2023-02-10 |
2023-04-11 |
上海交通大学 |
嵌合抗原受体nk细胞、制备方法及其用途
|
|
CN116731972A
(zh)
*
|
2023-02-10 |
2023-09-12 |
上海交通大学 |
嵌合抗原受体t细胞、制备方法及其用途
|
|
EP4687924A2
(en)
*
|
2023-03-24 |
2026-02-11 |
Board of Regents, The University of Texas System |
Engineered natural killer cells with enhanced antitumor memory responses
|
|
US20240358758A1
(en)
*
|
2023-04-07 |
2024-10-31 |
Nkarta, Inc. |
Methods for treatment of autoimmune diseases
|
|
CN116769722B
(zh)
*
|
2023-07-04 |
2024-07-16 |
杭州荣谷生物科技有限公司 |
功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025073908A1
(en)
*
|
2023-10-05 |
2025-04-10 |
Onk Therapeutics Limited |
Optimised il-15 constructs
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|